➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
AstraZeneca
Harvard Business School
Dow
Johnson and Johnson

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EFLORNITHINE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Eflornithine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003076 ↗ Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus Completed National Cancer Institute (NCI) Phase 2 1995-10-01 RATIONALE: Chemoprevention therapy is the use of drugs to try and prevent the development or recurrence of cancer. It is not known whether eflornithine is effective in preventing cancer in patients with Barrett's esophagus. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of eflornithine in preventing cancer in patients with Barrett's esophagus.
NCT00003076 ↗ Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus Completed University of Michigan Cancer Center Phase 2 1995-10-01 RATIONALE: Chemoprevention therapy is the use of drugs to try and prevent the development or recurrence of cancer. It is not known whether eflornithine is effective in preventing cancer in patients with Barrett's esophagus. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of eflornithine in preventing cancer in patients with Barrett's esophagus.
NCT00003814 ↗ Eflornithine in Treating Patients With Bladder Cancer Completed National Cancer Institute (NCI) Phase 3 1999-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if eflornithine is more effective than no further therapy in treating bladder cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of eflornithine in treating patients who have newly diagnosed or recurrent bladder cancer.
NCT00005882 ↗ Eflornithine Plus Sulindac in Preventing Colorectal Cancer in Patients With Benign Colorectal Polyps Completed Chao Family Comprehensive Cancer Center Phase 2 2000-06-01 RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of eflornithine and sulindac may be an effective way to prevent the development of colorectal cancer in patients who have had surgery to remove benign colorectal polyps. PURPOSE: Randomized, double-blinded, phase II trial to determine the effectiveness of eflornithine plus sulindac compared to a placebo in preventing colorectal cancer in patients who have had surgery to remove benign colorectal polyps.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Eflornithine Hydrochloride

Condition Name

Condition Name for Eflornithine Hydrochloride
Intervention Trials
Non-melanomatous Skin Cancer 3
Neuroblastoma 3
Familial Adenomatous Polyposis 3
Trypanosomiasis, African 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Eflornithine Hydrochloride
Intervention Trials
Colorectal Neoplasms 6
Trypanosomiasis, African 5
Trypanosomiasis 5
Neuroblastoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Eflornithine Hydrochloride

Trials by Country

Trials by Country for Eflornithine Hydrochloride
Location Trials
United States 187
Congo 10
Uganda 2
United Kingdom 2
Central African Republic 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Eflornithine Hydrochloride
Location Trials
Texas 11
California 11
Missouri 9
Florida 9
Pennsylvania 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Eflornithine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Eflornithine Hydrochloride
Clinical Trial Phase Trials
Phase 4 3
Phase 3 9
Phase 2/Phase 3 2
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Eflornithine Hydrochloride
Clinical Trial Phase Trials
Completed 14
Not yet recruiting 5
Recruiting 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Eflornithine Hydrochloride

Sponsor Name

Sponsor Name for Eflornithine Hydrochloride
Sponsor Trials
National Cancer Institute (NCI) 15
Giselle Sholler 4
Beat NB Cancer Foundation 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Eflornithine Hydrochloride
Sponsor Trials
Other 44
NIH 15
Industry 6
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Harvard Business School
McKesson
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.